Tarsus Pharmaceuticals Inc (TARS) - Net Assets
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has net assets worth $348.95 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($581.13 Million) and total liabilities ($232.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Tarsus Pharmaceuticals Inc operating cash flow efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $348.95 Million |
| % of Total Assets | 60.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | 105.98% |
| 10-Year Change | N/A |
| Growth Volatility | 18.97 |
Tarsus Pharmaceuticals Inc - Net Assets Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore TARS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Tarsus Pharmaceuticals Inc from 2018 to 2025. For live valuation and market cap data, see Tarsus Pharmaceuticals Inc (TARS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $343.43 Million | +52.95% |
| 2024-12-31 | $224.53 Million | +13.98% |
| 2023-12-31 | $196.99 Million | +2.12% |
| 2022-12-31 | $192.90 Million | +15.70% |
| 2021-12-31 | $166.73 Million | +0.45% |
| 2020-12-31 | $165.98 Million | +2864.03% |
| 2019-12-31 | $-6.00 Million | -343.50% |
| 2018-12-31 | $-1.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tarsus Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42526400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $381.00K | 0.11% |
| Other Components | $769.67 Million | 224.11% |
| Total Equity | $343.43 Million | 100.00% |
Tarsus Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Azelis Group NV
BR:AZE
|
$2.58 Billion |
|
Hanon Systems
KO:018880
|
$2.59 Billion |
|
Shanghai Tunnel Engineering Co Ltd
SHG:600820
|
$2.59 Billion |
|
American Eagle Outfitters Inc
NYSE:AEO
|
$2.59 Billion |
|
Beijing United Information Technology Co Ltd
SHG:603613
|
$2.58 Billion |
|
Investco Holding AS
IS:INVES
|
$2.58 Billion |
|
Songcheng Performance Develop
SHE:300144
|
$2.58 Billion |
|
KWS SAAT SE & Co. KGaA
F:KWS
|
$2.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tarsus Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 224,534,000 to 343,426,000, a change of 118,892,000 (53.0%).
- Net loss of 66,418,000 reduced equity.
- New share issuances of 134,771,000 increased equity.
- Other comprehensive income increased equity by 202,000.
- Other factors increased equity by 50,337,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-66.42 Million | -19.34% |
| Share Issuances | $134.77 Million | +39.24% |
| Other Comprehensive Income | $202.00K | +0.06% |
| Other Changes | $50.34 Million | +14.66% |
| Total Change | $- | 52.95% |
Book Value vs Market Value Analysis
This analysis compares Tarsus Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.32 | $60.06 | x |
| 2019-12-31 | $-0.31 | $60.06 | x |
| 2020-12-31 | $8.17 | $60.06 | x |
| 2021-12-31 | $8.11 | $60.06 | x |
| 2022-12-31 | $7.84 | $60.06 | x |
| 2023-12-31 | $6.70 | $60.06 | x |
| 2024-12-31 | $5.97 | $60.06 | x |
| 2025-12-31 | $8.22 | $60.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tarsus Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.72%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 1.64x
- Recent ROE (-19.34%) is above the historical average (-24.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.18 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.07 Million |
| 2020 | -16.15% | -80.20% | 0.19x | 1.04x | $-43.41 Million |
| 2021 | -8.29% | -24.25% | 0.32x | 1.07x | $-30.50 Million |
| 2022 | -32.19% | -240.51% | 0.11x | 1.18x | $-81.38 Million |
| 2023 | -68.99% | -778.89% | 0.07x | 1.35x | $-155.59 Million |
| 2024 | -51.46% | -63.16% | 0.49x | 1.68x | $-138.01 Million |
| 2025 | -19.34% | -14.72% | 0.80x | 1.64x | $-100.76 Million |
Industry Comparison
This section compares Tarsus Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc (TARS) | $348.95 Million | 0.00% | 0.67x | $2.58 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more